EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Di Wu, Jing Li, Dong Xu, Joan T Merrill, Ronald F van Vollenhoven, Yi Liu, Jiankang Hu, Yang Li, Fen Li, Chenghui Huang, Guochun Wang, Xiaomei Li und 18 weitere

Annals of the Rheumatic Diseases · 2024-04 · 83 (4) · 475-487

DOI: 10.1136/ard-2023-224854 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of the Rheumatic Diseases, 2024-04. Verfasst von Di Wu und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Recombinant Fusion Proteins. Die Arbeit wurde bisher 168-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, NIAID NIH HHS, RemeGen Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand, in active systemic lupus erythematosus (SLE). METHODS: Adult patients with active SLE (n=249) were recruited from 29 hospitals in China and randomised 1:1:1:1 to receive subcutaneous telitacicept at 80 mg (n=62), 160 mg (n=63), 240 mg (n=62) or placebo (n=62) once weekly in addition to standard therapy. The primary endpoint was the proportion of patients achieving an SLE Responder Index 4 (SRI-4) response at week 48. Missing data were imputed using the last observation carried forward method. RESULTS: At week 48, the proportion of patients achieving an SRI-4 response was 75.8% in the 240 mg telitacicept group, 68.3% in the 160 mg group, 71.0% in the 80 mg group and 33.9% in the placebo group (all p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicRecombinant Fusion ProteinsAdultHumansDouble-Blind MethodGlucocorticoidsSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

B-lymphocytesautoimmune diseasesbiological therapysystemic lupus erythematosus

Substanzen

GlucocorticoidsRecombinant Fusion Proteinstelitacicept

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immun…
  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.
  • Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • Department of Rheumatology and Immunology, Jiangxi Pingxiang People's Hospital, Pingxiang, Jiangxi, China.
  • Department of Rheumatology and Immunology, Guangdong People's Hospital, Guangzhou, Guangdong, China.

Förderung

  • NIAMS NIH HHS
  • NIAID NIH HHS
  • RemeGen Co., Ltd.
  • The National "Major New Drug Creation" Science and Technology Major Project

Zitieren

APA

Wu, D., Li, J., Xu, D., Merrill, J. T., van Vollenhoven, R. F., Liu, Y., Hu, J., Li, Y., Li, F., Huang, C., Wang, G., Li, X., Zhao, J., Zhao, D., Huang, C., Liu, H., Wei, W., Shi, G., Lu, F., …, & Zhang, F. (2024). Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 83(4), 475-487. https://doi.org/10.1136/ard-2023-224854

Vancouver

Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 2024;83(4):475-487. doi:10.1136/ard-2023-224854

BibTeX
@article{Wu2024,
  author = {Wu, Di and Li, Jing and Xu, Dong and Merrill, Joan T and van Vollenhoven, Ronald F and Liu, Yi and Hu, Jiankang and Li, Yang and Li, Fen and Huang, Chenghui and Wang, Guochun and Li, Xiaomei and Zhao, Jianhong and Zhao, Dongbao and Huang, Cibo and Liu, Huaxiang and Wei, Wei and Shi, Guixiu and Lu, Fuai and Zuo, Xiaoxia and Bi, Liqi and Li, Zhijun and Wang, Xiaoxia and Zhang, Miaojia and Tie, Ning and Li, Juan and Mo, Hanyou and Fang, Jianmin and Bao, Chunde and Zhang, Fengchun},
  title = {Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial},
  journal = {Annals of the Rheumatic Diseases},
  year = {2024},
  volume = {83},
  number = {4},
  pages = {475--487},
  doi = {10.1136/ard-2023-224854}
}
Kostenlos starten →